AAPL   259.81 (-5.01%)
FB   186.90 (-1.50%)
MSFT   155.18 (-1.90%)
GOOGL   1,274.37 (-3.09%)
AMZN   1,828.27 (-2.97%)
NVDA   250.06 (-1.01%)
BABA   201.03 (-1.95%)
MU   49.69 (-1.76%)
AMD   42.35 (-3.77%)
T   33.80 (-5.40%)
F   6.73 (-3.44%)
BAC   27.85 (-4.39%)
AAPL   259.81 (-5.01%)
FB   186.90 (-1.50%)
MSFT   155.18 (-1.90%)
GOOGL   1,274.37 (-3.09%)
AMZN   1,828.27 (-2.97%)
NVDA   250.06 (-1.01%)
BABA   201.03 (-1.95%)
MU   49.69 (-1.76%)
AMD   42.35 (-3.77%)
T   33.80 (-5.40%)
F   6.73 (-3.44%)
BAC   27.85 (-4.39%)
AAPL   259.81 (-5.01%)
FB   186.90 (-1.50%)
MSFT   155.18 (-1.90%)
GOOGL   1,274.37 (-3.09%)
AMZN   1,828.27 (-2.97%)
NVDA   250.06 (-1.01%)
BABA   201.03 (-1.95%)
MU   49.69 (-1.76%)
AMD   42.35 (-3.77%)
T   33.80 (-5.40%)
F   6.73 (-3.44%)
BAC   27.85 (-4.39%)
AAPL   259.81 (-5.01%)
FB   186.90 (-1.50%)
MSFT   155.18 (-1.90%)
GOOGL   1,274.37 (-3.09%)
AMZN   1,828.27 (-2.97%)
NVDA   250.06 (-1.01%)
BABA   201.03 (-1.95%)
MU   49.69 (-1.76%)
AMD   42.35 (-3.77%)
T   33.80 (-5.40%)
F   6.73 (-3.44%)
BAC   27.85 (-4.39%)
Log in

NYSEAMERICAN:PFNX - Pfenex Stock Price, Forecast & News

$12.00
-0.60 (-4.76 %)
(As of 02/28/2020 10:00 AM ET)
Today's Range
$11.46
Now: $12.00
$12.51
50-Day Range N/A
52-Week Range
$4.13
Now: $12.00
$14.00
Volume340,093 shs
Average Volume340,249 shs
Market Capitalization$380.11 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PFNX
Previous SymbolNYSEMKT:PFNX
CUSIPN/A
CIKN/A
Phone+1-858-3524400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees71
Market Cap$380.11 million
Next Earnings Date3/11/2020 (Confirmed)
OptionableOptionable

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.


Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. The biotechnology company earned $15.25 million during the quarter, compared to analyst estimates of $14.80 million. View Pfenex's Earnings History.

When is Pfenex's next earnings date?

Pfenex is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Pfenex.

How can I listen to Pfenex's earnings call?

Pfenex will be holding an earnings conference call on Wednesday, March 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for PFNX?

5 equities research analysts have issued twelve-month price targets for Pfenex's shares. Their forecasts range from $18.00 to $20.00. On average, they anticipate Pfenex's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 58.3% from the stock's current price. View Analyst Price Targets for Pfenex.

What is the consensus analysts' recommendation for Pfenex?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

Has Pfenex been receiving favorable news coverage?

Media headlines about PFNX stock have been trending very negative on Friday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pfenex earned a daily sentiment score of -3.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Pfenex.

Who are some of Pfenex's key competitors?

What other stocks do shareholders of Pfenex own?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 51)
  • Dr. Hubert C. Chen, Advisor (Age 50)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 55)

Who are Pfenex's major shareholders?

Pfenex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (11.26%), Blair William & Co. IL (8.22%), Renaissance Technologies LLC (4.99%), State Street Corp (1.82%), Geode Capital Management LLC (1.36%) and Sanders Morris Harris LLC (1.31%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Patrick K Lucy, Phillip M Schneider and Robin Campbell. View Institutional Ownership Trends for Pfenex.

Which institutional investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Royce & Associates LP, Marshall Wace LLP, Russell Investments Group Ltd., Acadian Asset Management LLC, Strs Ohio, Falcon Point Capital LLC and Jefferies Group LLC. View Insider Buying and Selling for Pfenex.

Which institutional investors are buying Pfenex stock?

PFNX stock was bought by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Jane Street Group LLC, Point72 Asset Management L.P., Calamos Advisors LLC, AQR Capital Management LLC, Charles Schwab Investment Management Inc., Renaissance Technologies LLC and Algert Global LLC. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Phillip M Schneider and Robin Campbell. View Insider Buying and Selling for Pfenex.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $12.00.

How big of a company is Pfenex?

Pfenex has a market capitalization of $380.11 million. Pfenex employs 71 workers across the globe.View Additional Information About Pfenex.

What is Pfenex's official website?

The official website for Pfenex is http://www.pfenex.com/.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.


MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  211 (Vote Underperform)
Total Votes:  411
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Google Finance Portfolio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel